Literature DB >> 10913712

Disappearance of tumor contrast on contrast-enhanced FLAIR imaging of cerebral gliomas.

M Essig1, S O Schoenberg, J Debus, G van Kaick.   

Abstract

Contrast-enhanced fluid-attentuated inversion recovery (FLAIR) magnetic resonance (MR) imaging has shown to be a valuable diagnostic modality in the assessment of cerebral gliomas. In this study we report of a potential pitfall regarding the delineation of enhancing tumor parts on contrast enhanced FLAIR imaging. In a limited number of patients, the administration of gadolinium obscures the area of contrast enhancement on contrast enhanced FLAIR images. Therefore the delineation of the macroscopic tumor parts, which are of great importance for the treatment planning is substantially worsened.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913712     DOI: 10.1016/s0730-725x(00)00139-9

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  4 in total

1.  MR imaging of leptomeningeal metastases: comparison of three sequences.

Authors:  Sanjay K Singh; Norman E Leeds; Lawrence E Ginsberg
Journal:  AJNR Am J Neuroradiol       Date:  2002-05       Impact factor: 3.825

2.  Differential diagnosis by unenhanced FLAIR T2-weighted magnetic resonance images between solitary high grade gliomas and cerebral metastases appearing as contrast-enhancing cortico-subcortical lesions.

Authors:  Carmine Franco Muccio; Annachiara Tarantino; Gennaro Esposito; Alfonso Cerase
Journal:  J Neurooncol       Date:  2010-11-11       Impact factor: 4.130

3.  Use of contrast-enhanced fluid-attenuated inversion recovery sequence to detect brain lesions in dogs and cats.

Authors:  K Merhof; J Lang; S Dürr; C Stahl; D Gorgas
Journal:  J Vet Intern Med       Date:  2014-06-24       Impact factor: 3.333

4.  Importance of Contrast-Enhanced Fluid-Attenuated Inversion Recovery Magnetic Resonance Imaging in Various Intracranial Pathologic Conditions.

Authors:  Eun Kyoung Lee; Eun Ja Lee; Sungwon Kim; Yong Seok Lee
Journal:  Korean J Radiol       Date:  2016-01-06       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.